Objectives: To evaluate the in vitro activity of ceftolozane/tazobactam and comparators tested against European isolates of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized patients with urinary tract infection or intraabdominal infections.
Introduction
Healthcare-associated infections (HCAI) are important causes of morbidity, mortality and excess medical costs worldwide. 1 Over half of all HCAI and associated antibiotic usage may be attributed to the management of lower respiratory tract infections, urinary tract infections (UTI) and intraabdominal infections (IAI). 1, 2 The spectrum of aetiological pathogens causing HCAIs is everchanging and varies from region to region and even from hospital to hospital. 1, 3 From the 1970s through 2000, the spectrum of HCAI pathogens shifted from Gram-negative bacilli (GNB) to include both Gram-positive cocci (GPC) and Candida spp. 1, [3] [4] [5] More recently, MDR GNB have become increasingly prevalent in the hospital setting. [6] [7] [8] [9] Population-based surveillance of antibiotic resistance in both Europe 10 and the USA 11 has documented increasing resistance among GNB in a large proportion of facilities. Prominent among the resistant species are ESBL-and carbapenem-resistant Enterobacteriaceae (CRE) and MDR (resistant to at least three antimicrobial classes) non-fermenters such as Pseudomonas aeruginosa. 6, 9, 12 Notably, this increase in resistance among GNB reduces the likelihood of appropriate empiric V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. therapy. 13 It is now well established that delay in initial appropriate therapy is associated with increased morbidity and mortality in patients with severe infections, particularly those caused by ESBLproducing Enterobacteriaceae 14 and P. aeruginosa. 13, 15 These findings underscore the continued importance of antibiotic resistance surveillance and the need to assess the potential impact of newly introduced and novel antibacterial agents targeting specific resistance phenotypes. 16, 17 Systematic and comprehensive antibiotic resistance surveillance is essential to document the extent of the resistance problem and to inform local, regional, national and global efforts to combat the challenge of resistance. 16 Ceftolozane/tazobactam is a novel antibacterial agent with activity against P. aeruginosa, including antibiotic-resistant strains, and other common GNB, including most ESBL-producing Enterobacteriaceae strains. [17] [18] [19] [20] [21] Ceftolozane/tazobactam is not active against Acinetobacter spp., Stenotrophomonas maltophilia, anaerobes, GPC or Enterobacteriaceae producing carbapenemases, metallo-b-lactamases and some AmpC b-lactamases. 17, 22 Ceftolozane/tazobactam has recently been approved for the treatment of complicated IAIs and complicated UTIs. 17 A Phase III clinical trial of ceftolozane/tazobactam in the treatment of nosocomial pneumonia is in progress.
In a previous antimicrobial resistance survey conducted in Europe in 2011-12, we described the in vitro activity of ceftolozane/ tazobactam tested against isolates of Enterobacteriaceae and P. aeruginosa from a variety of infection sites. 19, 20 In the present study, we extend these observations and focus on the activity of ceftolozane/tazobactam and selected b-lactam comparators against 6553 isolates of P. aeruginosa (603 isolates) and Enterobacteriaceae (5950 isolates) from patients with UTI or IAI hospitalized at 41 European medical centres (19 countries) during the period 2012-15. The analysis includes the activity of ceftolozane/tazobactam against specific resistance phenotypes (e.g. ESBL non-CRE phenotype and MDR strains of Enterobacteriaceae and P. aeruginosa) as well as the frequency of resistance patterns among the different European countries.
Materials and methods

Sampling sites and organisms
A total of 6553 GNB, including 5950 Enterobacteriaceae and 603 P. aeruginosa, were consecutively collected from 41 large academic medical centres located in 17 European countries plus Turkey and Israel by the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS). All organisms were isolated from hospitalized patients with documented UTI or IAI between January 2012 and December 2015 and only one isolate per patient infection episode was included in the surveillance collection. Species identification was performed at each participating medical centre and confirmed by the monitoring laboratory (JMI Laboratories, North Liberty, IA, USA) using the VITEK 2 System (bioMé rieux, Hazelwood, MO, USA) or MALDI-TOF MS (Bruker, Billerica, MA, USA), when necessary.
Antimicrobial susceptibility testing
MICs were determined using the reference CLSI broth microdilution method (CLSI, 2015) . 23 Quality control (QC) and interpretation of results were performed in accordance with CLSI M100-S26 and EUCAST 2016 guidelines (CLSI, 2016 24 ; EUCAST, 2016 25 ). Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Proteus mirabilis were grouped as 'ESBL phenotype' based on the CLSI screening criteria for potential ESBL production-i.e. MIC 2 mg/L for ceftazidime and/or ceftriaxone and/or aztreonam. 24 Ceftolozane/tazobactam activity JAC Table 1 . Antimicrobial activity of ceftolozane/tazobactam tested against the main organisms and organism groups of isolates in this study Pfaller et al. Tables 1 and 2 ). Among the b-lactam comparator agents tested, only meropenem was more active than ceftolozane/tazobactam against Klebsiella species irrespective of the resistant phenotype (Table 2) Tables 1 and 2) .
Activities of ceftolozane/tazobactam and comparators against Enterobacteriaceae
Previously (2012) we have shown that among European isolates of Enterobacteriaceae from patients with pneumonia, the rates of MDR and XDR phenotypes varied markedly from country to country. 19 As seen in Table 3 , resistance rates among Enterobacteriaceae causing either UTI or IAI also show considerable variability among the European nations evaluated. The occurrence of CRE, MDR and XDR Enterobacteriaceae was highest in Poland (29.9%, 72.2% and 32.0%, respectively) and lowest in Austria (0.0%, 3.1% and 0.0%, respectively), Denmark (0.0%, 4.2% and 0.0%, respectively), Finland (0.0%, 1.9% and 0.0%, respectively) and Switzerland (0.0%, 2.1% and 0.0%, respectively) ( Table 3 ). The highest rates of ESBL non-CRE phenotype Enterobacteriaceae were found in isolates from Poland (32.5%) and Turkey (36.2%) and the lowest were in isolates from Austria (0.0%), Finland (1.9%) and Switzerland (2.1%). The frequency of CRE was ,1.0% in 14 of the 19 countries contributing to the survey. Among the five major Western European countries (France, Germany, Italy, Spain and the UK), the occurrence of MDR Enterobacteriaceae was higher in Italy (18.4%) when compared with the other four countries (6.4%-12.6%) ( Table 3 ). These data are comparable to those reported in 2012 for respiratory tract isolates of Enterobacteriaceae from Europe. 19 Activities of ceftolozane/tazobactam and comparators against P. aeruginosa Tables 1 and 2 Table 2 ).
Ceftolozane/tazobactam retained moderate activity against isolates of P. aeruginosa that were NS to the other antipseudomonal b-lactam agents (Table 2) : ceftazidime-NS (65.5% susceptible), meropenem-NS (65.9%), cefepime-NS (61.3%) and piperacillin/ tazobactam-NS (70.4%). None of the other b-lactam agents inhibited .40.7% of these resistant phenotype isolates.
As observed in 2011-12, 20 P. aeruginosa susceptibility to antipseudomonal b-lactams varied markedly among the European nations that participated in the survey (Table 4 ). The lowest susceptibility rates for ceftazidime and meropenem were observed in Poland (46.9% and 34.4%, respectively) and Portugal (52.6% and 44.7%). Decreased susceptibility rates to ceftazidime and meropenem were also noted in Greece (61.1% for both compounds), Israel (69.2% and 76.9%, respectively), Italy (73.3% and 78.7%), Russia (20.0% for ceftazidime) and Turkey (63.6% and 70.5%). Ceftolozane/tazobactam activity was also compromised when tested against P. aeruginosa isolates from Greece (61.1% susceptible), Poland (75.0%), Portugal (63.2%) and Russia (60.0%), but it provided 100.0% coverage against isolates from 11 of the 19 countries (Table 4) . P. aeruginosa isolates from the five most populous Western European countries (i.e. France, Germany, Italy, Spain and the UK; 332 isolates) were more susceptible to ceftolozane/tazobactam (96.4%), ceftazidime (81.9%) and meropenem (84.9%) than isolates from 6 of the remaining 14 countries (Table 4) .
Discussion
The results of the present study both confirm and extend those previously reported concerning the in vitro activity of ceftolozane/ tazobactam against European isolates of Enterobacteriaceae and P. aeruginosa. [19] [20] [21] Ceftolozane/tazobactam was the most active of the tested b-lactam agents against P. aeruginosa and was second Ceftolozane/tazobactam activity JAC [18] [19] [20] [21] we found a great deal of variation in resistance rates to ceftazidime and meropenem with higher rates of resistance among European countries in the southern (Greece and Portugal) and eastern (Poland) countries versus northern countries (such as Germany, Ireland, Sweden and the UK). This pertains to both Enterobacteriaceae and P. aeruginosa (Tables 3 and 4 ) and has been shown to correlate with regional differences in b-lactamase production. 20 Whereas the spread of CRE is a major concern in Europe, the prevalence is variable. 20, 27 Higher prevalence rates of CRE have been reported in Greece, Italy, Turkey and Israel, with lower rates in the northern nations. 20, 27 Our results confirm these observations with CRE rates exceeding 1% in Greece (5.4%), Israel (1.2%), Italy (3.8%), Poland (29.9%) and Turkey (1.8%) (Table 3) . Notably, CRE were not identified in 7 of the 19 countries participating in the survey. High and variable rates of ESBL non-CRE phenotype and MDR Enterobacteriaceae are consistent with those previously reported by Farrell et al., 19 Sader et al. 20 and Canton et al.
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In summary, these data for ceftolozane/tazobactam collected in 2012-15 from 41 medical centres in 17 European countries plus Israel and Turkey demonstrated sustained potency and spectrum against Enterobacteriaceae and P. aeruginosa when compared to previous European studies. 20, 21 These data suggest that ceftolozane/tazobactam may be an important treatment option for UTI and IAI caused by both wild-type and MDR strains of P. aeruginosa and Enterobacteriaceae. 17 One of the more important aspects of this survey is the confirmation of extensive variation in antibioticresistant phenotypes of GNB across Europe. This finding emphasizes the need for ongoing surveillance and application of antimicrobial stewardship to prevent the further spread of b-lactam resistance. 16 Pfaller et al.
